{
    "clinical_study": {
        "@rank": "72230", 
        "arm_group": [
            {
                "arm_group_label": "Amoxicillin treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "after 3 day treatment of \u03b2-lactams, the subjects receive 5-day treatment of Amoxicillin. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry'  performed at Day 0, Day 30 and relapse"
            }, 
            {
                "arm_group_label": "placebo treatment", 
                "arm_group_type": "Placebo Comparator", 
                "description": "after 3-day treatment of \u03b2-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry'  performed at Day 0, Day 30 and relapse"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when\n      compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of\n      treatment in terms of clinical efficacy, in adults admitted to emergency services for a non\n      severe Community Acquired Pneumonia (PAC), who responded well to 3 days of beta-lactamin\n      treatment (3GC or A/AC)."
        }, 
        "brief_title": "Short Duration Treatment of Non-severe Community Acquired Pneumonia", 
        "condition": "Community Acquired Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must be 18 years old or over.\n\n          -  admitted three days before for Community Acquired Pneumonia (CAP) defined by at least\n             one clinical sign of pneumonia (dyspnea, cough, mucopurulent sputum, crackling sound\n             on lungs) associated with a temperature >38\u00b0C on admission, and a new infiltrate\n             consistent with pneumonia on chest x-ray, who responded favorably to 3 days of\n             treatment with \u03b2-lactams (third generation injectable cephalosporin or\n             amoxicillin-clavulanate)\n\n          -  able to take oral medication.\n\n          -  has given its informed consent.\n\n        Exclusion Criteria:\n\n          -  Creatinin < 30ml/min\n\n          -  History of jaundice / hepatic impairment associated with amoxicillin / clavulanic\n             acid\n\n          -  History of hypersensitivity to beta-lactam\n\n          -  Presence of complications or severity of pneumonia (abscess , significant pleural\n             effusion, severe chronic respiratory failure , septic shock, respiratory condition\n             requiring the passage resuscitation).\n\n          -  Known immunocompromised terrain ( asplenia , neutropenia, agammaglobulinemia ,\n             immunosuppressants, graft corticosteroids , myeloma , lymphoma, known HIV , sickle\n             cell anemia , CHILD C cirrhosis).\n\n          -  Antibiotic treatment exceeding 24 hours prior admission.\n\n          -  Suspected atypical bacteria requiring combined antibiotics therapy .(Subjects who\n             received a single dose of macrolides or fluoroquinolones emergency will not be\n             excluded) .\n\n          -  Legionella suspected on clinical, biological and radiological criteria .\n\n          -  Subjects with clinical or epidemiological environment leading to suspect a\n             healthcare-associated pneumonia with antibiotic resistant pathogen.\n\n          -  Suspicion of pneumonia by aspiration.\n\n          -  Intercurrent infection requiring antibiotic treatment.\n\n          -  Pregnant women .\n\n          -  Breastfeeding .\n\n          -  Allergy to antibiotics in use.\n\n          -  Life expectancy <1 month .\n\n          -  Subject without health insurance.\n\n          -  Subjects without home adress"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963442", 
            "org_study_id": "PHRC-12-0021.927-PTC", 
            "secondary_id": "2013-000265-36"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Amoxicillin treatment", 
                    "placebo treatment"
                ], 
                "description": "at Day 0, Day 30 and relapse", 
                "intervention_name": "Chest X-ray", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Amoxicillin treatment", 
                    "placebo treatment"
                ], 
                "intervention_name": "blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Amoxicillin treatment", 
                "description": "2 tablets 3 times a day for 5 days from Day 3", 
                "intervention_name": "Augmentin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo treatment", 
                "description": "2 tablets 3 times a day for 5 days from Day 3", 
                "intervention_name": "Placebo (for Augmentin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Amoxicillin treatment", 
                    "placebo treatment"
                ], 
                "description": "administered from Day 0 to Day 3", 
                "intervention_name": "Beta-Lactams", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lactams", 
                "Amoxicillin-Potassium Clavulanate Combination", 
                "Beta-Lactams"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Garches", 
                    "country": "France", 
                    "zip": "92380"
                }, 
                "name": "Central Hospital Raymon Poincar\u00e9"
            }, 
            "investigator": {
                "last_name": "Anne-Claude CREMIEUX, PH", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Non-Inferiority, Multicentered, Controlled, Randomized, Double Blinded Study Investigating the Antibiotic Treatment Duration (3-day Versus 8-day) for Subjects Admitted to Emergency Services With Acute Non-severe Community Acquired Pneumonia (CAP)", 
        "other_outcome": {
            "measure": "mortality all causes at Day 30", 
            "safety_issue": "No", 
            "time_frame": "Day 30"
        }, 
        "overall_contact": {
            "email": "anne-claude.cremieux@rpc.aphp.fr", 
            "last_name": "Anne-Claude CREMIEUX, PH", 
            "phone": "0033147107730"
        }, 
        "overall_official": {
            "affiliation": "Central Hospital Raymon Poincar\u00e9", 
            "last_name": "Anne-Claude CREMIEUX, PH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: National Drug Security Agency (ANSM)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical evaluation at Day 15 composed of the composite measure of the Clinical examination for clinical symptoms of CAP, recording of the body temperature and confirmation that no additionnal antibiotic treatment was required from Day 8", 
            "measure": "clinical evaluation at Day 15", 
            "safety_issue": "No", 
            "time_frame": "Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963442"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Central Hospital, Versailles", 
            "investigator_full_name": "Anne-claude Cremieux", 
            "investigator_title": "Clinical Coordinator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Clinical evaluation at Day 30 composed of the composite measure of the Clinical examination for clinical symptoms of CAP, recording of the body temperature and Evaluation of replapse or aggravation of pneumonia or any other respiratory infections in subjects considered cured at Day 15.", 
            "measure": "clinical evaluation at Day 30", 
            "safety_issue": "Yes", 
            "time_frame": "Day 30"
        }, 
        "source": "Central Hospital, Versailles", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Central Hospital, Versailles", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}